FilingPulse

AVBP insider transaction filings

ArriVent BioPharma, Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-22. Screen AVBP transaction legs live →

Insider transaction summary — last 90 days

No Form 4 filings for AVBP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.

Recent Form 4 filings — ArriVent BioPharma, Inc.

FiledFormInsiderReported transactionsSource
2026-06-224Parsey Merdad — DirectorGrant/award (A): 13,562 (derivative) @ $0EDGAR
2026-06-224Nolet Chris — DirectorGrant/award (A): 13,562 (derivative) @ $0EDGAR
2026-06-224Hohneker John — DirectorGrant/award (A): 13,562 (derivative) @ $0EDGAR
2026-06-224Peterson Kristine — DirectorGrant/award (A): 13,562 (derivative) @ $0EDGAR
2026-02-044LaChapelle Robin — Chief Operating OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2026-02-044Lutzker Stuart — President of R&D, DirectorGrant/award (A): 150,000 (derivative) @ $0EDGAR
2026-02-044Kastenmayer James Paul — General CounselGrant/award (A): 130,000 (derivative) @ $0EDGAR
2026-02-044Kung Winston — Chief Financial OfficerGrant/award (A): 140,000 (derivative) @ $0EDGAR
2026-02-044Yao Zhengbin — President and CEO, DirectorGrant/award (A): 550,000 (derivative) @ $0EDGAR
2026-02-034HILLHOUSE INVESTMENT MANAGEMENT, LTD. — 10% owner
HHLR ADVISORS, LTD. — 10% owner		Sale (S): 555,555 @ $23.37EDGAR
2025-07-154LaChapelle Robin — Chief Operating OfficerOption exercise (M): 2,050 @ $2.28 · Option exercise (M): 2,600 @ $2.28 · Option exercise (M): 6,503 @ $2.28 · Option exercise (M): 2,050 (derivative) @ $0 · Option exercise (M): 2,600 (derivative) @ $0 · Option exercise (M): 6,503 (derivative) @ $0EDGAR
2025-06-204Parsey Merdad — DirectorGrant/award (A): 15,502 (derivative) @ $0EDGAR
2025-06-204Nolet Chris — DirectorGrant/award (A): 15,502 (derivative) @ $0EDGAR
2025-06-204Hohneker John — DirectorGrant/award (A): 15,502 (derivative) @ $0EDGAR
2025-06-204Peterson Kristine — DirectorGrant/award (A): 15,502 (derivative) @ $0EDGAR
2025-04-294Parsey Merdad — DirectorGrant/award (A): 28,346 (derivative) @ $0EDGAR
2025-02-144Lutzker Stuart — President of R&D, DirectorGrant/award (A): 120,000 (derivative) @ $0EDGAR
2025-02-144LaChapelle Robin — Chief Operating OfficerGrant/award (A): 120,000 (derivative) @ $0EDGAR
2025-02-144Kastenmayer James Paul — General CounselGrant/award (A): 102,000 (derivative) @ $0EDGAR
2025-02-144Kung Winston — Chief Financial OfficerGrant/award (A): 120,000 (derivative) @ $0EDGAR
2025-02-144Yao Zhengbin — President and CEO, DirectorGrant/award (A): 380,000 (derivative) @ $0EDGAR
2024-09-234LaChapelle Robin — Chief Operating OfficerOption exercise (M): 2,700 @ $6.24 · Option exercise (M): 2,867 @ $2.28 · Option exercise (M): 7,164 @ $2.28 · Option exercise (M): 2,471 @ $2.28 · Option exercise (M): 12,364 @ $3.65 · Option exercise (M): 2,471 (derivative) @ $0 · +4 moreEDGAR
2024-05-204Hohneker John — DirectorGrant/award (A): 29,550 (derivative) @ $0EDGAR
2024-04-234Peterson Kristine — DirectorGrant/award (A): 28,587 (derivative) @ $0EDGAR
2024-02-014HILLHOUSE INVESTMENT MANAGEMENT, LTD. — 10% owner
HHLR ADVISORS, LTD. — 10% owner		Conversion (C): 3,616,041 · Conversion (C): 313,076 · Purchase (P): 555,555 @ $18 · Conversion (C): 55,000,000 (derivative) @ $0 · Conversion (C): 4,761,903 (derivative) @ $0EDGAR
2024-01-314GORDON CARL L — Director, 10% ownerConversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 moreEDGAR
2024-01-314HEALY JAMES — DirectorConversion (C): 1,252,308 · Purchase (P): 444,444 @ $18 · Conversion (C): 1,252,308 (derivative)EDGAR
2024-01-314ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VIII LLC — Director, 10% owner
OrbiMed Advisors IV Ltd — Director, 10% owner
OrbiMed Asia GP IV, L.P. — Director, 10% owner		Conversion (C): 821,827 · Conversion (C): 821,827 · Conversion (C): 469,615 · Conversion (C): 469,615 · Purchase (P): 222,222 @ $18 · Purchase (P): 222,222 @ $18 · +4 moreEDGAR
2024-01-294Nolet Chris — DirectorGrant/award (A): 17,884 (derivative) @ $0EDGAR
2024-01-294Jallal Bahija — DirectorGrant/award (A): 17,884 (derivative) @ $0EDGAR

Recent 8-K events — ArriVent BioPharma, Inc.

FiledFormItems reportedSource
2026-08-128-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-228-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-118-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-178-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-11-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-09-098-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-07-218-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AVBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →